drugset / Trial / NCT01959685

A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal

NCT01959685

Phase 1 Completed 9 enrolled Repros Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

To determine the tolerability and pharmacokinetics (PK) of a single dose of Androxal in healthy adult male subjects as the dose to be investigated in a thorough QT interval/corrected QT interval (QT/QTc) study.

Timeline

Start
2013-10
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Androxal Unknown 125 mg
Subject Androxal Unknown 250 mg

Indications

No indication recorded.